Clinical Study of CAR-iNKT Cells in the Treatment of Relapsed/Refractory/High-risk B-cell Tumors
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Acute Lymphoblastic Leukemia
- B Cell Lymphoma
- Chronic Lymphocytic Leukemia
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 5 years and 70 years
- Gender
- Both males and females
Description
CD19 CAR-T has been shown to treat a variety of refractory or recurrent B-cell tumors. Because most CAR-T cells are generated from the patient's own T cells and are individualized products, and there are individual differences between patients, the generation of customized CAR-T cells is an expensiv...
CD19 CAR-T has been shown to treat a variety of refractory or recurrent B-cell tumors. Because most CAR-T cells are generated from the patient's own T cells and are individualized products, and there are individual differences between patients, the generation of customized CAR-T cells is an expensive and time-consuming process. Universal CAR- iNKT cells are an ideal product for cell therapy. In this study, we prepared universal iNKT cells expressing hCD19 CAR and IL-15 to treat refractory, relapsed, or high-risk B-cell tumors.
Tracking Information
- NCT #
- NCT04814004
- Collaborators
- North Jiangsu People's Hospital
- The First People's Hospital of Changzhou
- Nantong University
- First Affiliated Hospital of Zhejiang University
- Affiliated Hospital of Jiangsu University
- Huai 'an First People's Hospital
- Investigators
- Study Chair: Kailin Xu, Ph.d The Affiliated Hospital of Xuzhou Medical University Study Director: Junnian Zheng, Ph.D Xuzhou Medical University
Get Well Soon